structur
longsought
elus
goal
hiv
biologist
difficulti
work
membran
protein
strong
tendenc
aggreg
hurdl
stood
way
chan
et
weissenhorn
et
final
produc
first
structur
follow
shortli
tan
et
began
give
molecular
form
apparatu
viral
fusion
whose
outlin
emerg
earlier
decad
structur
focu
much
work
design
new
inhibitor
fusion
process
serv
outstand
exampl
find
basic
scienc
stimul
explor
new
therapeut
fusion
look
like
envelop
spike
compos
decor
surfac
surfac
glycoprotein
spike
engag
coreceptor
primarili
macrophag
cell
undergo
conform
chang
activ
transmembran
glycoprotein
use
conserv
structur
element
mediat
fusion
host
viral
membran
genet
inform
flow
viru
target
cell
structur
spike
dictat
viru
need
bind
enter
target
cell
avoid
host
neutral
antibodi
respons
respons
host
antibodi
bind
viru
prevent
enter
target
cell
manag
problem
evolv
keep
vulner
conserv
region
envelop
compris
fusion
much
possibl
serv
two
purpos
restrict
abil
conserv
epitop
elicit
antibodi
low
immunogen
help
prevent
antibodi
elicit
bind
conserv
epitop
low
antigen
neutral
antibodi
conserv
epitop
particular
threat
escap
via
mutat
difficult
variabl
region
envelop
spike
matur
untrigg
spike
much
surfac
mask
receptor
engag
perhap
vulner
access
fusionintermedi
state
restrict
close
oppos
membran
fusion
process
take
minut
significantli
limit
access
transient
expos
epitop
contrast
postfus
conform
stabl
repeat
unit
highli
immunogen
postfus
conform
appear
radic
differ
fusionintermedi
conform
elicit
antibodi
unabl
bind
intermedi
conform
therefor
unabl
inhibit
fusion
descript
given
molecular
underpin
xray
crystal
structur
put
postfus
form
ref
known
n
ctermin
portion
extern
domain
contain
heptad
repeat
sequenc
peptid
correspond
ntermin
nhr
ctermin
chr
heptad
repeat
region
notabl
respect
could
inhibit
entri
rebrand
enfuvirtid
approv
us
food
drug
administr
patient
last
fall
overcom
technic
hurdl
crystal
necessari
truncat
protein
make
stabl
solubl
three
laboratori
crystal
proteolyt
stabl
core
extravir
domain
devoid
ntermin
hydrophob
fusion
peptid
disulfideloop
region
link
nhr
chr
region
membraneproxim
region
although
group
crystal
fragment
differ
size
result
structur
nearli
ident
found
trimer
core
consist
parallel
correspond
nhr
region
pack
around
trimer
core
three
slightli
obliqu
chr
arrang
antiparallel
inner
core
creat
trimer
heterodim
sixhelix
bundl
fig
notabl
arrang
also
observ
phinduc
conform
influenza
hemagglutinin
transmembran
subunit
moloney
murin
leukemia
structur
motif
sinc
found
ebola
viru
newcastl
diseas
viru
respiratori
syncyti
viru
coronaviru
link
sever
acut
respiratori
motif
strike
exampl
converg
evolut
reveal
vulner
exploit
drug
design
structur
provid
understand
fusion
inhibitor
work
shed
light
difficulti
design
vaccin
elicit
neutral
antibodi
peptid
correspond
chr
region
inhibit
entri
pack
outer
groov
trimer
therebi
prevent
format
sixhelix
resist
document
typic
involv
one
two
substitut
along
outer
groov
nhr
region
rel
new
drug
peptid
analog
effect
inhibitor
isol
clinic
trial
http
wwwtrimeriscompipelineclinicalhtml
resist
anticip
yet
document
peptid
correspond
nhr
region
inhibit
sixhelix
bundl
format
target
chr
region
monomer
nhr
peptid
prone
aggreg
make
much
less
potent
potenc
increas
substanti
solubl
trimer
nhr
principl
antibodi
could
bind
nhr
inner
helic
core
receptor
activ
also
block
entri
similar
fusion
inhibitor
term
vaccin
design
howev
elicit
neutral
antibodi
target
may
difficult
spatial
tempor
limit
fusion
process
broadli
neutral
antibodi
defin
date
seem
recogn
epitop
close
viral
membran
access
vaccinologist
await
structur
fusion
intermedi
structur
stimul
progress
design
select
fusion
inhibitor
one
studi
engin
trimer
inner
nhr
helic
peptid
use
select
peptid
random
phage
display
librari
peptid
select
proteolyt
stabl
mirrorimag
dpeptid
potent
inhibit
entri
anoth
studi
investig
construct
fivehelix
bundl
lack
one
outer
chr
peptid
fivehelix
bundl
potent
inhibit
entri
probabl
bind
singl
chr
region
prevent
sixhelix
bundl
particularli
inspir
demonstr
structurebas
design
solventexpos
residu
one
face
chr
peptid
substitut
onto
solventexpos
face
anoth
helic
scaffold
inde
result
hybrid
peptid
block
entri
major
problem
peptid
therapeut
includ
cost
difficulti
manufactur
current
cost
per
year
per
patient
suppli
yet
satisfi
demand
initi
effort
develop
nonpeptid
inhibitor
entri
use
crystal
structur
molecular
dock
algorithm
use
search
small
molecul
librari
silico
compound
might
bind
deep
hydrophob
caviti
inner
nhr
peptid
core
bestrank
compound
inhibit
infect
modest
potenc
anoth
group
use
short
chr
peptid
scaffold
attach
nonpeptid
combinatori
librari
onto
n
terminu
librari
screen
engin
trimer
nhr
peptid
hybrid
ligand
compos
synthet
moieti
link
chr
peptid
select
abl
inhibit
cellcel
optim
nonpeptid
moieti
envis
rout
standalon
smallmolecul
fusion
inhibitor
anoth
approach
small
molecul
design
mimic
hydrophob
surfac
along
one
face
heptad
repeat
proteomimet
abl
partial
disrupt
sixhelix
bundl
inhibit
mediat
hidden
secret
continu
reveal
new
lead
therapi
vaccin
emerg
interest
new
target
intervent
may
uncov
obtain
detail
structur
inform
nativ
fusionintermedi
conform
also
use
elucid
influenc
structur
function
segment
omit
crystal
structur
smallmolecul
drug
design
extrem
effect
inhibit
proteas
revers
transcriptas
remain
seen
well
work
envelop
complex
sinc
drug
resist
preval
alreadi
document
drug
cocktail
may
best
solut
inde
rang
potenti
target
grow
arsen
entri
make
synergi
exist
futur
drug
combin
excit
possibl
materi
part
natur
medicin
year
anniversari
seri
content
relat
special
focu
issu
pleas
see
http
wwwnaturecomnmspecialfocusanniversaryindexhtml
